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Abstract
Introduction We conducted a prospective observational study
from January 1995 to December 2004 to evaluate the impact on
recovery of a major advance in renal replacement therapy,
namely continuous veno-venous haemodiafiltration (CVVHDF),
in patients with refractory septic shock.
Method CVVHDF was implemented after 6–12 hours of
maximal haemodynamic support, and base excess monitoring
was used to evaluate the improvement achieved. Of the 60
patients studied, 40 had improved metabolic acidosis after 12
hours of CVVHDF, with a progressive improvement in all failing
organs; the final mortality rate in this subgroup was 30%. In
contrast, metabolic acidosis did not improve in the remaining 20
patients after 12 hours of CVVHDF, and the mortality rate in this
subgroup was 100%. The crude mortality rate for the whole
group was 53%, which is significantly lower than the predicted
mortality using Simplified Acute Physiology Score II (79%).
Conclusion Early CVVHDF may improve the prognosis of
sepsis-related multiple organ failure. Failure to correct metabolic
acidosis rapidly during the procedure was a strong predictor of
mortality.
Introduction
Septic shock is usually accompanied by acute renal injury, her-
alded by a drop in diuresis. However, when standard intermit-
tent haemodialysis (IHD) is used to treat renal failure, the
initiation of renal replacement therapy is often delayed by con-
cerns about haemodynamic tolerance. With the availability of
continuous veno-venous haemofiltration, a safe procedure in
haemodynamically unstable patients [1], there is no reason to
delay renal replacement therapy [2]. Moreover, haemofiltration
has been reported to improve cardiopulmonary function in
septic patients, even if they are not oliguric [3,4].
Based on these findings, in January 1995 we began to treat
sepsis-related multiple organ failure with early continuous
veno-venous haemofiltration combined with continuous veno-
venous haemodiafiltration (CVVHDF). This strategy was our
standard clinical practice for 10 years (from January 1995 to
December 2004) and was accepted as a routine procedure by
the Ethics Committee of the Société de Réanimation de
Langue Française (Paris, France). Our clinical results are pre-
sented in this report, which focuses on the relation between
rapid correction of metabolic acidosis with early renal replace-
ment therapy and mortality.
Materials and methods
Patients
Between January 1995 and December 2004, all patients
meeting at the same time criteria for sepsis, refractory circula-
tory failure, acute renal injury, and acute lung injury were
included in the study, and data were prospectively collected
for later analysis. Sepsis was defined as at least two of the fol-
lowing conditions occurring within the context of infection:
temperature above 38°C or below 36°C, heart rate above 90
beats/minute, and white blood cell count above 12,000 or
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below 4,000 cells/mm2 [5]. The causative bacterial agent was
subsequently identified based on positive culture (blood or a
sample from a localized site of infection) in 70% of cases.
Refractory circulatory failure was defined as a persistent or
growing metabolic acidosis despite adequate vasoactive sup-
port over an observation period of 6–12 hours, and was
judged to be present if there was a base excess below -5
mmol/l at the end of this period. Acute renal injury was defined
as a urinary output below 30 ml/hour during the period of
observation [6]. Finally, acute lung injury was defined as an
arterial oxygen tension/fractional inspired oxygen ratio below
300 mmHg and need for mechanical ventilation. However,
patients meeting inclusion criteria but with a rapidly fatal
underlying medical condition (McCabe score 2) were
excluded.
Haemodynamic monitoring and initial management of 
circulatory failure
Arterial pressure was monitored using an indwelling radial
artery catheter, and central venous pressure was monitored
using an internal jugular venous catheter. All patients had
hypotension at admission (primary shock) or exhibited acute
hypotension during their stay in the unit (secondary shock),
defined as an arterial systolic pressure lower than 90 mmHg,
as determined by invasive monitoring. This hypotension per-
sisted despite aggressive fluid challenge and required contin-
uous noradrenaline (norepinephrine) infusion. Fluid
resuscitation was performed by administering 10–20 ml/kg
plasma expanders (6% Hetastarch) over 30 minutes, followed
by administration of enough crystalloids to achieve a central
venous pressure of 12 mmHg or greater rapidly. Continuous
infusion of noradrenaline was started at 0.1 µg/kg per minute
and was progressively increased until a systolic radial pres-
sure above 90 mmHg was achieved. Bedside echocardiogra-
phy was used to measure cardiac index (using the Doppler
technique) and left ventricular ejection fraction, as previously
described [7]. Dobutamine was added at 5 µg/kg per minute
when left ventricular ejection fraction was found to be lower
than 40% on transthoracic or transoesophageal bedside
echocardiography [7]. In cases in which circulatory improve-
ment was judged to be insufficient with this combination (i.e.
persistent and severe left ventricular systolic dysfunction by
echocardiography), dobutamine was replaced by adrenaline
(epinephrine) infusion at 0.5–2 µg/kg per minute [7].
Additional therapies
All of the patients also required mechanical ventilation
because of associated acute lung injury or acute respiratory
distress syndrome, which was an inclusion criterion. Our strat-
egy of low-stretch mechanical ventilation was reported previ-
ously [8]. In addition, 17 patients from the group received low-
dose corticosteroids. This additional therapy was systemati-
cally used in our unit from January 2002, as has been recom-
mended in the management of septic shock [9]. No patients
received drotrecogin alfa (activated). Finally, all patients were
given antibiotics in consultation with a microbiologist, accord-
ing to culture findings.
Severity indices
In all patients, a general severity index (the Simplified Acute
Physiology Score [SAPS] II [10]) was calculated at admission.
An organ dysfunction index (the Logistic Organ Dysfunction
Score [11]) was calculated at admission (primary shock) or at
the onset of circulatory failure (secondary shock). We also cal-
culated the probability of hospital mortality (predicted mortal-
ity) using SAPS II and the 'standardized mortality ratio' by
dividing the observed by the predicted hospital mortality. The
severity of the patient's underlying medical condition was
stratified using the McCabe score [12] as nonfatal (score 0)
or ultimately fatal (score 1). As stated above, patients with a
rapidly fatal underlying medical condition (McCabe score 2)
were excluded. We also noted the presence or absence of a
condition known to be associated with immunological
incompetence.
Veno-venous haemodiafiltration
CVVHDF was considered at the end of the observational
period if a growing metabolic acidosis was observed, as
defined above. Each CVVHDF session was performed using a
Prisma pump (Hospal, Lyon, France). For vascular access, a
double lumen catheter (Mahurkar, 11.5 Fr; Tyco Healthcare
Group, Mansfield, MA, USA) was inserted percutaneously into
either the right internal jugular vein or the femoral vein using
the Seldinger technique. Blood flow was driven at 150 ml/
minute through the polyacrylonitrile haemofilter (AN 69; Hos-
pal). Ultrafiltration was maintained at 2,000 ml/hour. The ultra-
filtrate was replaced by bicarbonate-buffered haemofiltration
fluid (Hemosol B0; Hospal). Dialysate (bicarbonate 32 mEq/l;
Hemosol B0; Hospal) flow rate was maintained at 1,000 ml/
hour. The anticoagulant was intravenous heparin, with an initial
bolus of 2,000–3,000 IU, followed by 300 IU/kg per day to
maintain the patient's activated clotting time at 60–70 s.
Figure 1
Number of patients included per year during the 10-year period of  observation Number of patients included per year during the 10-year period of 
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Blood glucose checks were performed regularly during the
procedure, and both hyperglycaemia (sometimes present in
septic patients) and hypoglycaemia (related to the procedure)
were immediately corrected.
Each session of CVVHDF lasted 3 days, with the same filter,
and was followed by 2 or 3 days without CVVHDF. In five
cases, however, early clotting after 12–24 hours required an
immediate change in filter in order to follow the 3-day protocol.
CVVHDF was then repeated for 3 days if necessary, until renal
recovery. During the first session of CVVHDF a strictly neutral
fluid balance was maintained, using the digital balance
included in the Prisma pump. During the following sessions, a
negative fluid balance was instituted if necessary.
Statistical analysis
Statistical calculations were performed using the Statgraphics
plus package (Manugistics, Rockville, MD, USA). Data are
expressed as mean ± standard deviation or (in figures) as box
and whisker plot analyses. Between group comparisons were
performed using the χ2 test with Yates' correction for categor-
ical variables, and with the Mann–Whitney U test for continu-
ous variables. A Wilcoxon signed rank test was used to
compare paired variables. Cumulative survival curves were
compared using the log rank test. Linear regression analysis
was also performed when required.
Results
The study group included 38 men and 22 women, whose
mean age was 57 ± 16 years. The average measured body
weight was 72 ± 13 kg. Circulatory failure was present at
admission in 44 patients (primary shock) or occurred after sev-
eral days of hospitalization in our unit in 16 patients (secondary
shock). The number of patients included per year during this
10-year period is presented in Figure 1. These patients were
predominantly medical (45 medical patients versus 15 surgi-
cal patients). The causative bacterial agent was subsequently
identified from a positive blood culture or from a localized site
of infection in 42 cases; Gram-positive and Gram-negative
agents were responsible in 22 and 20 patients, respectively.
The average SAPS II score for the whole group was 67 ± 18.
During the same period, 35 patients who met the inclusion cri-
teria but with a rapidly fatal underlying disease (McCabe score
2) were excluded from the study.
Individual changes in base excess during the observational
period, defining refractory circulatory failure, are shown in Fig-
ure 2, and the trend in base deficit after 12 hours of CVVHDF
was used to separate patients into two groups. In 40 respond-
ers (group 1), metabolic acidosis was reduced by the first 12
hours of CVVHVD. In 20 nonresponders (group 2), metabolic
acidosis was unchanged or even deteriorated after 12 hours
of CVVHDF (Figure 2). Table 1 summarizes the main physio-
logical data for both groups. No between-group difference
was observed apart from a significantly higher Logistic Organ
Dysfunction Score in group 2. Mortality rate was 30% in group
1 and 100% in group 2 (P < 0.0000; Table 1 and Figure 3).
Twenty-eight patients recovered and 32 ultimately died, lead-
ing to a crude mortality rate of 53% for the whole group. This
mortality rate was significantly lower than that predicted by
SAPS II (79%; P = 0.01) leading to an standardized mortality
ratio of 0.67.
Metabolic acidosis
As stated above, metabolic acidosis was judged to be present
if there was a base excess below -5 mmol/l at the end of the
period of observation. All patients studied exhibited an
increased blood lactate level at the end of the period of obser-
vation (5 ± 3 mmol/l, range 1.5–16.4 mmol/l). Individual blood
lactate values were inversely and significantly correlated with
individual base excess values (r = -0.61; P < 0.001). Plasma
Figure 2
Individual changes in base excess Individual changes in base excess. Shown are individual changes in base excess in (a) responders (group 1) and (b) nonresponders (group 2) over 
the 6- to 12-hour observation period (h 0 to h 6–12) and during the first 24 hours of CVVHDF. CVVHDF begins at h 6–12 on the x-axis; the patients 
have undergone 12 hours of CVVHDF at h 12 on the x-axis; finally, the patients have undergone 24 hours of CVVHDF at h 24 on the x-axis. 
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Table 1
Comparison of physiological data between group 1 and group 2.
Parameter Group 1 (n = 40) Group 2 (n = 20) P value
Age (years) 56 ± 16 58 ± 16 0.56
SAPS II score 61 ± 13 72 ± 21 0.08
LODS score 13 ± 1.8 14.6 ± 3.2 0.02
McCabe score (n [%])
0 31(77) 15 (82) 1
1 9 (23) 5 (28)
Immuno-incompetent (n [%]) 8 (20) 7 (35) 0.34
Shock (n [%])
Primary 28 (70) 16 (80) 0.61
Secondary 12 (30) 4 (20)
Reason for admission (n [%])
Medical 29 (72) 16 (80) 0.75
Surgical 11 (26) 4 (20)
Aetiological agent identified (n [%])
Yes 31 (78) 11 (55) 0.14
No 9 (22) 9 (45)
Corticosteroid therapy (n [%]) 12 (30) 5 (25) 0.92
Mortality (%)
Predicted 67 87 <0.0001
Observed 30 100
In group 1 (responders), there were 22 cases of bacterial pneumonia and eight cases of sepsis of extrapulmonary origin among medical patients, 
and 10 cases of peritonitis among surgical patients. In group 2 (nonresponders) there were 11 cases of bacterial pneumonia and seven cases of 
sepsis of extrapulmonary origin among medical patients, and two cases of peritonitis among surgical patients. No significant difference was found 
between these distributions. LODS, Logistic Organ Dysfunction Score; SAPS, Simplified Acute Physiology Score.
Figure 3
Cumulative survival Cumulative survival. Shown are cumulative survival curves in group 1 
(responder) and group 2 (nonresponder) patients, showing better out-
come in group 1 (P < 0.0001, log rank test).
Table 2
Average plasma electrolyte concentrations before CVVHDF
Electrolytes Group 1 (n = 40) Group 2 (n = 20)
Cations (mEq/l)
Sodium 134 ± 5 135 ± 4
Potassium 4 ± 1 5 ± 1*
Anions (mEq/l)
Chloride 98 ± 6 98 ± 4
Bicarbonate 17 ± 5 16 ± 5
Phosphate 1.9 ± 0.9 2.6 ± 0.9 *
Protein 12 ± 3 12 ± 4
*P < 0.05. CVVHDF, veno-venous haemodiafiltration.Available online http://ccforum.com/content/9/6/R755
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anion gap was calculated as follows: (sodium + potassium) –
(chloride + bicarbonate). Our laboratory's normal value for
anion gap is 16 mmol/l, and all patients studied except for one
exhibited a widened anion gap (25 ± 6 mmol/l, range 11.6–
43.8 mmol/l). Individual values for anion gap were inversely
and significantly correlated with individual values for base
excess (r = -0.62; P < 0.001). Plasma phosphate was also sig-
nificantly increased (2.1 ± 0.9 mmol/l, range 0.6–4.4 mmol/l),
and we also found a significant inverse correlation between
individual values of plasma phosphate and base excess (r = -
0.48, P = 0.002).
Average plasma electrolyte concentrations for both groups
measured before CVVHDF implementation are presented and
compared in Table 2.
Refractory circulatory failure
During the period of observation, haemodynamic support
involved noradrenaline infusion alone in 28 patients, noradren-
aline combined with dobutamine in 11 patients, and adrenaline
in 21 patients. Average dosages of major catecholamines (for
example, calculated by summation of adrenaline and noradren-
aline instantaneous doses) are presented in Table 3 and are
illustrated in Figure 4. This support was guided by repeated
bedside echocardiographic examination, as previously
described [7]. Table 3 summarizes the haemodynamic data
recorded at the end of the observational period for both
groups. The arterial oxygen tension/inspired fractional oxygen
ratio was significantly lower in group 2. Blood lactate level at
the end of the observational period and vasoactive support,
based on catecholamine dosage, were also significantly
greater in group 2.
Rapid improvement in circulatory status was observed in 36 of
the 40 group 1 patients, heralded by a significantly lower cat-
Table 3
Blood gas analysis and haemodynamic parameters at the end of the 6-hour observational period
Parameter Group 1 (n = 40) Group 2 (n = 20) P value
PaO2/FiO2 (mmHg) 139 ± 68 100 ± 68 0.046*
PaCO2 (mmHg) 49 ± 11 53 ± 12 0.18
BE (mmol/l) -11 ± 4 -13 ± 5 0.10
pH 7.17 ± 0.11 7.11 ± 0.13 0.06
Lactate (mmol/l) 4.3 ± 1.8 5.8 ± 3.2 0.020*
HR (beats/minute) 118 ± 20 113 ± 20 0.48
CI (l/minute per m2) 3.2 ± 1.2 2.9 ± 1 0.39
LVEF (%) 50 ± 16 48 ± 19 0.73
Vasopressor support (choice; n [%])
Noradrenaline 19 (48%) 9 (45%) 0.97
Noradrenaline + dobutamine 7 (18%) 4 (20%)
Adrenaline 14 (35%) 7 (35%)
Vasopressor support (dosage; µg/kg per minute) 1.1 ± 0.8 2.3 ± 1.4 0.002*
Shown is a comparison of blood gas analysis and haemodynamic parameters at the end of the 6-hour observational period between group 1 
(responders) and group 2 (nonresponders). Vasopressor dosage is the cumulative dosage of major catecholamines (noradrenaline 
[norepinephrine] or adrenaline [epinephrine]), with dobutamine being given at 5 µg/kg per minute. *Statistically significant finding. BE, base 
excess; CI, cardiac index; FiO2, fractional inspired oxygen; HR, heart rate; LVEF, left ventricular ejection fraction; PaCO2, arterial carbon dioxide 
tension; PaO2, arterial oxygen tension.
Figure 4
Changes in the amounts of catecholamines required Changes in the amounts of catecholamines required. Shown are box 
and whisker plot analyses (median = horizontal line inside the box; 
mean = point inside the box) of changes in the amount of catecho-
lamines required at onset of CVVHDF (h 6–12 on the x-axis) and after 
24 hours of the procedure (h24 on the x-axis) in (a) group 1 (respond-
ers) and (b) group 2 (nonresponders). A significant reduction in need 
for catecholamines was observed in group 1 during CVVHDF (*P < 
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echolamine requirement after 24 hours of CVVHDF (Figure 4;
P < 0.001). However, in four cases circulatory failure did not
improve during CVVHDF, circulatory status worsened in the
hours following the end of the first session, and complete
withdrawal from vasoactive support was never possible. These
four patients died after an average of 4.5 ± 2.4 days of
haemodynamic support with a vasoactive agent. In the 36
remaining patients complete withdrawal of vasoactive support
was possible at the end of the first session, or it could be with-
drawn gradually over the following days. Twenty-eight patients
ultimately recovered, after 28 ± 19 days of respiratory support.
Eight patients later died from recurrence of circulatory failure
(n = 4) or from a lethal neurological complication (n = 4),
including an intracranial haemorrhage in one patient. A lower
catecholamine requirement during CVVHDF was not
observed in group 2 patients (Figure 4). Conversely, the need
for catecholamines, which was unchanged or increased dur-
ing CVVHDF, increased during the hours following the first
session, and all the patients in this group died, after an average
of 3.5 ± 2.5 days of haemodynamic support with a vasoactive
agent.
Acute renal injury
In this group of 60 patients with refractory septic shock, acute
renal injury was defined as diuresis below 30 ml/hour during
the observational period of 6–12 hours. In 12 surgical
patients, initially managed during the period of observation in
the surgical intensive care unit of our hospital, intravenous
administration of 500–1,000 mg furosemide failed to increase
diuresis. Average plasma urea concentration at the end of the
observational period was 16 ± 11 mmol/l and the average
serum creatinine was 248 ± 141 µmol/l. There was no signif-
icant difference between groups in plasma urea concentration
(18 ± 12 mmol/l in group 1 versus 14 ± 8 mmol/l in group 2)
or in serum creatinine (255 ± 140 µmol/l in group 1 versus
241 ± 148 µmol/l in group 2).
A rapid improvement in renal function was observed on aver-
age in group 1 patients, heralded by resumption of diuresis
after 24 hours of CVVHDF (Figure 5). In the four group 1
patients who died without any substantial improvement in cir-
culatory status, renal function did not improve. In contrast,
complete recovery of renal function was observed in 18
patients at the end of the first session. In 18 other patients
renal function improved more slowly, and one (n = 9), two (n
= 6), or three (n  = 3) additional CVVHDF sessions were
required before complete renal recovery occurred. During the
second session, a negative fluid balance of 5.6 ± 2.9 l (range
1.9–12.2 l) was obtained in these still anuric patients, without
any haemodynamic support. Three patients, who remained
anuric after three or four CVVHVD sessions, required addi-
tional supportive treatment by IHD. Ultimate recovery of renal
function was achieved in two cases, but one patient unfortu-
nately died from a neurological complication before renal
recovery. Conversely, group 2 patients did not exhibit any
improvement in renal function during the procedure (Figure 5).
Finally, no blood infusion was required for bleeding related to
CVVHDF.
Additional therapies
Seventeen patients also received corticosteroid treatment.
Mortality in this specific subgroup was 53%, which was no dif-
ferent from that for the whole group (53%).
Discussion
Septic shock is a condition in which renal perfusion is mark-
edly impaired [13], producing acute renal injury [6]. Use of
noradrenaline to maintain arterial pressure classically worsens
renal hypoperfusion in the low output state [6], but it may
improve this perfusion in the hyperdynamic state, a frequent
pattern in septic shock [14]. However, when shock becomes
refractory, an acute renal failure syndrome may also develop
[6]. Even if it is essentially of prerenal origin, renal function is
stopped and renal replacement therapy appears logical.
Unfortunately, conventional IHD frequently worsens circulatory
status in haemodynamically unstable patients, and renal
replacement therapy by this method is usually delayed,
pending circulatory improvement [4]. Moreover, conventional
IHD is usually considered only when metabolic disorders asso-
ciated with organic renal failure are marked [15], which is not
usually the case after an interruption to diuresis of only 6–12
hours. Both of these conditions impose an obligatory delay,
during which most patients with refractory shock die.
An important finding of the present study was that a rapid met-
abolic improvement occurred during early CVVHDF in 67% of
patients with refractory septic shock (group 1). Of course, the
metabolic acidosis observed in our patients, which was asso-
ciated with an increased lactate level, was interpreted as
Figure 5
Changes in diuresis Changes in diuresis. Shown are box and whisker plot analysis (median 
= horizontal line inside the box; mean = point inside the box) of change 
in diuresis during the first 24 hours of CVVHDF in (a) group 1 
(responders) and (b) group 2 (nonresponders). A significant increase in 
diuresis was observed on average in group 1 (*P < 0.001). CVVHDF, 
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mainly resulting from circulatory failure. It was thus considered
a consequence, not a cause, of circulatory failure. However, as
indicated by abnormally high values of plasma phosphate, pre-
renal failure contributed in part to the metabolic acidosis. Thus,
despite a short duration of renal impairment, renal acidosis
was actually present. However, the metabolic improvement
observed in group 1 did not appear to result mainly from the
buffering action of CVVHDF, because it was associated with
a circulatory improvement, permitting a rapid reduction in
vasoactive support. This finding is at variance with clinical
observations made during IHD. In a recent clinical report,
despite adherence to practice guidelines, conventional IHD
was associated with a drop in arterial pressure and with
increased need for catecholamines in the majority of patients
[16].
Concerning the evolution of renal function, the haemodynamic
improvement observed during the first CVVHDF session in
group 1 patients was associated with rapid renal recovery in
half of the patients, as expected with a renal failure of prerenal
origin. In the remaining patients from this group, however, this
recovery was more progressive, suggesting that some tubular
necrosis might have occurred. In these latter cases, additional
CVVHDF sessions were required because of delayed
recovery of renal function. Moreover, these additional sessions
permitted rapid removal of the large volume of fluid given for
resuscitation once circulatory failure had been corrected. This
beneficial result is impossible with IHD, as was recently illus-
trated by the report cited above [16], in which only minimal
reduction in body weight could be achieved at the end of renal
replacement therapy. In three cases, in whom renal recovery
was markedly delayed, renal replacement therapy was com-
pleted by IHD, which is a perfectly safe procedure when tem-
porally distant from the initial haemodynamic problems.
Another important finding was that lack of metabolic improve-
ment after 12 hours of CVVHDF (for example, unchanged
base deficit despite the buffering action of CVVHDF) was
associated with a 100% mortality rate. This finding of failure to
improve metabolically after 12 hours might be important
because it suggests that application of CVVHDF might be
futile in such cases. Conversely, the lack of metabolic improve-
ment after 12 hours of CVVHDF might prompt use of drotrec-
ogin alfa, an expensive but efficient treatment for septic shock
[17]. The lack of improvement in base deficit after 24 hours of
active treatment was recently underscored as a strong predic-
tor of mortality in critically ill patients [18], suggesting the
importance of this dosage in the monitoring of septic shock. In
that report, a base deficit above 2.5 mmol/l or a blood lactate
level greater than 1 mmol/l after 24 hours of adequate support
were respectively associated with mortality rates of 71% and
82%.
The particularly poor prognosis of refractory septic shock has
led some authors to consider whether strong vasoactive sup-
port may be futile in this setting [19]. In this latter report, septic
shock initially treated by dopamine and requiring subsequent
noradrenaline infusion was associated with a 85% mortality
rate. In another report [20] septic patients exhibiting at least
three organ failures, as did our patients, had a mortality rate of
92%. The duration of lactic acidosis was found to be a good
predictor of multiple organ failure [21], and early lactate clear-
ance was associated with an improved outcome from septic
shock in another study [22]. In this context, our strategy of
using early CVVHDF appeared to represent a rescue proce-
dure; the final mortality rate of 53% for the whole group was
significantly and markedly lower than that predicted by SAPS
II (79%). However, this finding needs confirmation in prospec-
tive comparative studies. Despite our somewhat different pro-
cedure, including only middle volume haemofiltration,
continuous dialysis and use of the same filter throughout the
session, our results are similar to those recently reported by
Honore and coworkers [23]. In a group of 20 patients with
refractory septic shock, whose SAPS II score was in the same
range as that for our patients, those authors observed a mor-
tality rate of 55%, in contrast to the predicted mortality of 79%.
Our present data suggest that early renal replacement therapy
by CVVHDF might have a beneficial effect as an adjunctive
treatment for refractory septic shock. This therefore raises a
major question about the precise mechanism by which
CVVHDF may improve this condition. Many humoral mediators
that are potentially involved in the inflammatory response asso-
ciated with sepsis are 'middle molecules', which are cleared by
the technique. For this purpose, convection has been proved
to be more efficient than diffusion [24]. However, recent stud-
ies have yielded conflicting results. De Vriese and coworkers
[25] demonstrated effective cytokine removal in patients with
septic shock, but in a recent phase II randomized study Cole
and coworkers [26] were unable to confirm that early use of
haemofiltration at a filtration rate of 2 l/hour reduced the circu-
lating concentration of cytokines associated with septic
shock. Increasing the rate of fluid exchange across the mem-
brane will increase convective transport, and this led the same
group of investigators to suggest that high-volume haemofiltra-
tion might improve clearance of mediators in refractory septic
shock [27]. In the present study we did not use high-volume
haemofiltration, as defined by Ronco and coworkers [28] as a
threshold of 35 ml/kg per hour. Use of 2,000 ml/hour haemo-
filtration in our group of patients, whose average body weight
was 72 kg, would have resulted in an average convection
exchange of 28 ml/kg per hour. However, in a recent study
Cole and coworkers [27] compared high-volume versus
standard-volume haemofiltration in a group of 11 septic
patients, and found that both techniques lowered the plasma
concentration of mediators. The kinetics of this decrease sug-
gested that it mainly resulted from membrane adsorption,
which was achieved with both techniques, and in a recent pro/
con debate the benefit of high-volume haemofiltration was
challenged [29]. Thus, membrane adsorption might beCritical Care    Vol 9 No 6    Page et al.
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responsible, at least to some extent, for the haemodynamic
improvement observed in the present study.
However, early and adequate renal replacement therapy might
also have contributed to the improved prognosis. Acute renal
failure per se exerts an independent and specific effect on the
morbidity of critically ill patients [30,31]. The mortality rate in
acute renal failure occurring in a septic context was 75% in a
large prospective study, in which IHD was the quasi-exclusive
therapeutic procedure [32]. Critically ill patients probably ben-
efit from a combination of diffusion and convection that pro-
vides sufficient elimination of small and larger toxins and, in
contrast to the majority of other reports, we combined dialysis
with our procedure, anticipating better treatment of renal fail-
ure syndrome [33]. Also, this technique probably permitted a
more rapid correction of metabolic acidosis by acting on the
renal component of this disorder. However, if it should be con-
sidered, any impact of this choice on the clinical outcome
remains purely hypothetical.
Conclusion
Without providing any idea regarding the precise mechanism,
which would require additional comparative studies, our clini-
cal report suggests that early renal replacement therapy by
CVVHDF may improve the prognosis of the most severe forms
of septic shock, and should be considered as an adjunctive
therapy in sepsis-related multiple organ failure. Moreover, after
12 hours, this procedure distinguishes a subgroup of patients
with a 100% probability of death and so it could perhaps help
in deciding whether to institute a more expensive treatment,
such as drotrecogin alfa.
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